Kenvue
Summit, New Jersey, United States · Health Care
Kenvue is a consumer health spinoff of Johnson & Johnson, specializing in global corporate affairs and a portfolio of brands including Band-Aid, Listerine, Tylenol, and Neutrogena.
Key facts
- Headquarters
- Summit, New Jersey, United States
- Employees
- 17,791
- Industries
- Health Care
- Status
- Public (KVUE)
- Website
- www.kenvue.com
- Company page
Recent activity at Kenvue
- : SEC 8-K (5.02): On November 1, 2026, a change of control occurred in the Company as a result of the First Merger, where the Initial Surviving Company became a direct wholly owned subsidiary of K-C. The Cash Consideration was funded through a combination of cash reserves, debt financing, and proceeds from a prior sale of a 51% interest in K-C's International Family Care and Professional business. Additionally, there were significant changes in the board of directors as all prior members resigned and new directors from First Merger Sub were appointed. This change is expected to impact the governance structure and strategic direction of the Company following the mergers.
- : SEC 8-K (1.01):
- : SEC 8-K (5.07): Kenvue Inc. held its 2026 Annual Meeting of Shareholders on May 21, 2026, where shareholders voted on several proposals, including the election of all 12 director nominees to the Board of Directors. These directors are set to serve until the 2027 Annual Meeting of Shareholders. The voting results reflect strong support with over 1.5 billion votes in favor for the nominated directors, indicating unified shareholder approval for the company's leadership structure moving forward.
- : Kenvue Partners with Greyparrot to Enhance Sustainable Packaging with AI Technology.
- : SEC 8-K (5.02): On April 10, 2026, Kenvue Inc. appointed Heather Howlett as the interim Chief Financial Officer, effective May 12, 2026, following the announced departure of current CFO Amit Banati. Ms. Howlett, age 48, has been with the Company as Chief Accounting Officer since May 2023 and has prior experience in similar roles at Trane Technologies and Johnson & Johnson. In connection with her new role, Ms. Howlett will receive a monthly stipend of $125,000 on top of her existing compensation package. No other changes to her compensation or benefits will occur due to this appointment. This transition reflects the Company's strategic planning in leadership changes and succession management.
- : SEC 8-K (2.05): On February 17, 2026, the Company's Board of Directors approved a restructuring initiative aimed at optimizing the operating model and reducing complexity to drive operational efficiencies. This initiative will lead to a net global workforce reduction of approximately 3.5% and is expected to incur pre-tax restructuring expenses totaling around $250 million in fiscal year 2026. The costs will comprise approximately 59% for information technology and project-related expenses, 35% for employee-related costs, and 6% for other implementation costs. The estimates are preliminary and subject to change based on various regulatory requirements, indicating potential strategic implications for the company's future operations and financial performance.
- : SEC 8-K (5.02): On February 10, 2026, Amit Banati notified Kenvue Inc. that he would step down as Chief Financial Officer effective May 12, 2026, to pursue a CEO opportunity at another company. Kenvue plans to appoint a successor as the principal financial officer on an interim basis, especially in light of a pending transaction with Kimberly-Clark Corporation. Banati will work closely with the leadership team for three months to ensure a smooth transition of responsibilities. This management change could impact the financial strategies during this critical transitional period as the company navigates its dealings with Kimberly-Clark.
- : SEC 8-K (7.01): On January 29, 2026, Kenvue Inc. and K-C issued a joint press release to announce the preliminary results of their Special Meeting and the results of a corresponding special meeting of K-C's shareholders. This disclosure is presented as Item 7.01 under Regulation FD, indicating that the information shared is not intended to be filed but to inform shareholders. The release aims to keep stakeholders abreast of key developments and is significant given its timing related to upcoming strategic decisions.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On November 2, 2025, Kenvue appointed Kirk L. Perry as its permanent Chief Executive Officer, effective immediately. Mr. Perry has been serving as interim CEO since July 2025 and will continue as a member of the Kenvue Board. Under the terms of his new Offer Letter, Mr. Perry will receive an annual base salary of $1,350,000, eligibility for an annual bonus targeting 175% of his salary starting in 2026, and an equity award valued at approximately $9.29 million. Additionally, he may earn a transaction bonus of up to $4 million, contingent upon his continued employment and performance evaluation. This appointment reflects Kenvue's strategic move to solidify leadership after interim management.
Leadership
- Andrew Stanleick, President, Skin Health & Beauty, North America and EMEA at Kenvue
- Trilok Kumar, EMEA Labeling Projects Hub Lead (Global Capability Center)
- Eduardo Valera, Sr. Recruiter | Sr. Talent Acquisition Partner - On Behalf of @Cielo Talent
- Sohyla Elawam, Senior Regulatory Affairs Specialist- Jordan
- Vasily Kutsevol, Talent Access Head Emea
- Saranya Roy, 🔍 🕵🏼 Financial Crime Compliance(FCC) Professional |🎓BSc in Applied Science @ UNoM|⚖ Business Law
- Ruchi Panjwani, Talent Access Partner - Commercial Hiring India
- Usman Syed, Senior Manager - Asset Management and Engineering Standards - Regional Lead EMEA APAC
- Asrining Tyas, Head of People, Indonesia
- Giovana Oliveira, Sr. Talent Acquisition Partner At
Verified email and direct lines for Kenvue’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Kenvue files 6 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Kenvue in the news
- Neutrogena®, Aveeno® and Rogaine® release new dermatology research and clinical skincare innovations on healthy aging, moisturization, sun protection and acne - Kenvue (Mar 27, 2026)
- Kenvue Inc. - Investor Relations - Kenvue Investor Relations (May 04, 2023)
- Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue - Kenvue Investor Relations (Jan 29, 2026)
- Kenvue unveils foundational consumer trends report A New View of Care - A new view of care - Kenvue (Aug 19, 2025)
- Kenvue releases second annual Healthy Lives Mission report - Kenvue (Jun 26, 2025)
- Kenvue to announce second quarter 2026 results on August 6, 2026 - Kenvue (Jul 23, 2026)
- Science in action: Kenvue research driving real-life solutions - Kenvue (Jul 17, 2025)
- Kenvue introduces patented micro-peptide technology with Neutrogena® Collagen Bank™ launch - Kenvue (Aug 15, 2024)
Companies similar to Kenvue
- Sandoz · Health Care
- Wellstar Health System · Health Care
- IKS Health · Health Care
- STERIS plc · Health Care
- Affidea · Health Care
About Kenvue: questions and answers
What does Kenvue do?
Kenvue is a consumer health spinoff of Johnson & Johnson, specializing in global corporate affairs and a portfolio of brands including Band-Aid, Listerine, Tylenol, and Neutrogena.
Where is Kenvue headquartered?
Kenvue is headquartered in Summit, New Jersey, United States.
How many employees does Kenvue have?
Kenvue has about 17,791 employees.
Who leads Kenvue?
Andrew Stanleick is a President, Skin Health & Beauty, North America and EMEA at Kenvue at Kenvue.
What is the latest news on Kenvue?
On Nov 02, 2026, SEC 8-K (5.02): On November 1, 2026, a change of control occurred in the Company as a result of the First Merger, where the Initial Surviving Company became a direct wholly owned subsidiary of K-C. The Cash Consideration was funded through a combination of cash reserves, debt financing, and proceeds
Is Kenvue a public company?
Yes. Kenvue is publicly traded under the ticker KVUE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy